Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;15(3):327-33.
doi: 10.1586/14737175.2015.996551.

Building a roadmap for developing combination therapies for Alzheimer's disease

Daniel Perry  1 , Reisa Sperling, Russell Katz, Donald Berry, David Dilts, Debra Hanna, Stephen Salloway, John Q Trojanowski, Chas Bountra, Michael Krams, Johan Luthman, Steven Potkin, Val Gribkoff, Robert Temple, Yaning Wang, Maria C Carrillo, Diane Stephenson, Heather Snyder, Enchi Liu, Tony Ware, John McKew, F Owen Fields, Lisa J Bain, Cynthia Bens
Affiliations
Review

Building a roadmap for developing combination therapies for Alzheimer's disease

Daniel Perry et al. Expert Rev Neurother. 2015 Mar.

Abstract

Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.

Keywords: Alzheimer’ disease; co-development; collaboration; combination therapy; novel therapy.

PubMed Disclaimer

References

    1. Stephenson D, Perry D, Bens C, Bain LJ, Berry DA, Krams M, Sperling R, Dilts D, Luthman J, Hanna D, et al. Charting a path toward combination therapy for Alzheimer's disease. 2012 http://act-ad.org/wp-content/uploads/2014/05/Combination-therapy-for-AD_.... - PubMed
    1. Food and Drug Administration. Guidance for Industry: Enrichment strategies for clinical trials to support approval of human drug and biological products. [accessed online 7/18/2013];2012 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
    1. Food and Drug Administration. Draft Guidance for Industry. Alzheimer's disease: Developing drugs for the treatment of early stage disease. [Accessed 2-24-2013];2013 at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
    1. Food and Drug Administration. Guidance for industry: Codevelopment of two or more unmarketed investigational drugs for use in combination. [Accessed online 4/13/14];2010 at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid....
    1. Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119–128. - PMC - PubMed

LinkOut - more resources